Gain Therapeutics Inc

Gain Therapeutics harnesses its Magellan™ platform to uncover hidden allosteric sites, advancing promising Parkinson’s candidate GT‑02287 and new neuro‑disorder therapies.

Gain Therapeutics uses a proprietary allosteric‑site platform to unlock new treatments for protein‑misfolding diseases, redefining drug discovery and precision medicine.

Gain Therapeutics innovates drug discovery with an allosteric target platform, offering new hope for protein‑misfolding diseases despite early‑stage financial challenges.

Gain Therapeutics, Inc. is a biotech company that is taking a bold approach to drug discovery, but its innovative strategy also carries significant financial risks and competitive pressures.